Neurology · Washington
Neurology studies in Washington
63 studies have at least one recruiting site in Washington. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
63 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Bellevue, WA + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Bellevue, WA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Seattle, WA + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Hillhurst Biopharmaceuticals, Inc.
- Location
- Spokane, WA + 4 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Spokane, WA + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- Seattle, WA + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Seattle, WA + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Seattle, WA + 4 other US sites
- Eligibility basics
- Ages 2–12
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Seattle, WA + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Zydus Therapeutics Inc.
- Location
- Seattle, WA + 13 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
- Location
- Seattle, WA + 4 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 1/Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron Pharmaceuticals
- Location
- Seattle, WA + 8 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Seattle, WA + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Kirkland, WA + 33 other US sites
- Eligibility basics
- Ages 45–75
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- Tacoma, WA + 30 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Spokane, WA + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
- Location
- Bellevue, WA + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Eli Lilly and Company
- Location
- Bellevue, WA + 41 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Seattle, WA + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Two Dose Levels of Privigen in Pediatric CIDP
CSL Behring
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 2–17
- Recruiting
Use of CereGate Therapy for Freezing of Gait in PD
CereGate Inc.
- Location
- Seattle, WA + 6 other US sites
- Eligibility basics
- Ages 21–80
- RecruitingPhase 2
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
- Location
- Seattle, WA + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Michael Shy
- Location
- Seattle, WA + 17 other US sites
- Eligibility basics
- Any age listed
- RecruitingHealthy volunteers
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
University of Iowa
- Location
- Seattle, WA + 17 other US sites
- Eligibility basics
- Any age listed
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.